Abstract: Cow’s milk allergy (CMA) continues to be a growing health concern for infants living in Western countries. The long-term prognosis for the majority of affected infants is good, with about 80% naturally acquiring tolerance by the age of four years. However, recent studies suggest that the natural history of CMA is changing, with an increasing persistence until later ages. The pathogenesis of CMA, as well as oral tolerance, is complex and not completely known, although numerous studies implicate gut-associated immunity and enteric microflora, and it has been suggested that an altered composition of intestinal microflora results in an unbalanced local and systemic immune response to food allergens. In addition, there are qualitative and quantitative differences in the composition of gut microbiota between patients affected by CMA and healthy infants. These findings prompt the concept that specific beneficial bacteria from the human intestinal microflora, designated probiotics, could restore intestinal homeostasis and prevent or alleviate allergy, at least in part by interacting with the intestinal immune cells. The aim of this paper is to review what is currently known about the use of probiotics as dietary supplements in CMA.

Keywords: food allergy; probiotics; intestinal microflora; immune system; tolerance acquisition
1. Introduction

During the last decade, we observed a changing pattern in cow’s milk allergy (CMA), the most common food allergy in childhood. An increased prevalence, severity of clinical manifestations and risk of persistence was demonstrated in Western countries [1]. In Italy, CMA is responsible for 42% of food-induced anaphylaxis in the pediatric population [2].

Much evidence indicates the development of intestinal microflora as a crucial factor for immune system maturation and tolerance acquisition [3]. Early epidemiological studies supported the idea that environment-induced alterations in the composition of intestinal microflora play a central role in the development of allergic diseases [4]. A recently developed ultra-high-throughput sequencer, called a pyrosequencer, allowed sequence-based 16S rRNA profiling of microbiota, confirming the presence of gut dysbiosis in allergic infants. In particular, a decrease in selected *Firmicutes* species and an increase in *Bacteroidetes* species was demonstrated [5]. For more than a century, probiotics have been used as a therapeutic/preventive strategy for a variety of gastrointestinal disorders, restoring the intestinal microflora. The World Health Organization (WHO)/Food and Agriculture Organization of the United Nations (FAO) define probiotics as live microorganisms that, when consumed in adequate amounts as part of food or as oral supplements, confer a health benefit on the host [6]. Probiotics research and the industry have continued to grow from these early observations, and the global sales of probiotic ingredients are expected to reach $31.1 billion by 2015, with an annual growth rate of 7.6% for the next few years [7]. Despite the plethora of basic research data, probiotic clinical research in food allergy is still in its infancy, but the most recent evidence supports the potential clinical impact derived from a manipulation of intestinal microflora as a disrupting strategy to efficiently address the changing pattern of CMA.

2. Oral Tolerance and Intestinal Microflora

Food antigens and intestinal microflora constitute the majority of the antigen load in the intestine, and the “default” reaction of the immune system confronted with them leads to systemic unresponsiveness. This phenomenon is known as oral tolerance and is a key feature of intestinal immunity [8]. The complex interaction between intestinal contents and immune and non-immune cells results in an environment that favors tolerance by the induction of IgA antibodies and CD4+ T regulatory cells (producing IL-10 and IFN-γ) [3]. This ensures that a homeostatic balance is maintained between the intestinal immune system and its antigen load, so that it retains the ability to recognize dangerous and harmless antigens as foreign and preserves the integrity of the intestinal mucosa.

The inappropriate immune response to food, which is responsible for food allergy, is the result of a deregulation of these crucial processes [9]. An allergic reaction mainly corresponds to the activation of Th2 cells against food allergens and occurs in two phases: the first phase corresponds to transport of the allergen through the intestinal barrier, its capture by antigen presenting cells, dendritic cells (DCs) or enterocytes, and its presentation to naive Th0 cells, which differentiate in the presence of IL-4 into Th2 cells. Activated Th2 cells then produce an IL-4 cytokine that enables the production of allergen-specific IgE by B-cells [10]. These secreted IgEs then bind to mast cells via the IgE receptor, FcεRI. The activation phase corresponds to the degranulation of mast cells after further exposure to the
same allergen that links directly with specific IgE on the surface of these cells. This phenomenon triggers release of the allergic mediators involved in clinical manifestations of allergy. Recent data strongly suggest that gut microbiota is important for oral tolerance development [11] (see Figure 1).

**Figure 1.** Intestinal microflora drives oral tolerance development. Under homeostatic condition, antigens from selected components of intestinal microflora are acquired in the lamina propria and presented in the mesenteric lymphnodes by CD 103+ dendritic cells. Through mechanisms mainly involving transforming growth factor (TGF) β and retinoic acid, dendritic cells induce the production of gut homing Treg cells. Treg cells actively suppress allergic sensitization to food.

Basic research involving microbiology, biology, immunology and genetics is providing interesting insights on the delicate network driving to oral tolerance. Studies on germ-free mice revealed a failure in the acquisition of tolerance to food proteins. Mice with food allergy exhibit a specific gut microbiota signature capable of transmitting disease susceptibility. Transplanted healthy infant microbiota had a protective impact on sensitization and CMA in mice. Finally, polymorphisms in or deficiency of microbial sensors for bacterial lipopolysaccharide (LPS) (TLR-4) are associated to food allergy [12,13]. The spore-forming component of indigenous intestinal microbiota, particularly clusters IV and XIVa of the genus *Clostridium*, promote Treg cell accumulation. Colonization of mice by a defined mix of *Clostridium* strains provides an environment rich in TGF β and affected Foxp3+ Treg number and function in the colon. Oral inoculation of *Clostridium* during the early life of conventionally reared mice results in resistance to allergic colitis and systemic immunoglobulin E responses in adult mice, suggesting a new therapeutic approach to food allergy [14]. In this light, it is important to consider that after four weeks of treatment with the probiotic *Lactobacillus rhamnosus* GG (LGG), it is possible to induce a significant increase in clostridia in milk-hypersensitive subjects [15].

3. **Probiotics and Their Mechanisms of Action**

Probiotics have pleiotropic effects that occur within the intestinal lumen or within and beyond the intestinal mucosa (Table 1). Local influences of probiotics include: hydrolysis of antigenic peptides in the gut lumen, modulation of intestinal permeability and reduction of systemic penetration of antigens, increased local IgA production and modulation of local inflammation and stimulation of epithelial cell...
growth and differentiation [16–19]. Some systemic activities consist of anti-inflammatory effects mediated by toll-like receptors (TLRs), Th1 skewing of responses to allergens and activation of tolerogenic DCs, in addition to T regulatory cell production and tolerance acquisition [20,21].

**Table 1.** Schematic representation of the mechanisms of action of probiotics implicated in allergy prevention and treatment.

| Effects | |
|---------|---|
| Within intestinal lumen | ➢ Modulation of intestinal microflora [16]  
➢ Increased local IgA production [17]  
➢ Hydrolysis of antigenic peptides [18] |
| At mucosal level | ➢ Modulation of intestinal permeability [19]  
➢ Stimulation of cell growth and differentiation [20] |
| Beyond the intestinal mucosa | ➢ Modulation of innate/adaptive immune system [3]  
➢ Induction of oral tolerance [3]  
➢ Impact on the enteric nervous system [21] |

It is becoming evident that completely different effects may be observed, depending on the species and the strain of the microorganism used [22]. Recent in vivo studies in healthy human volunteers measured the changes in gene transcription profiles to determine the molecular responses that occur in the human duodenal mucosa following consumption of probiotic Lactobacillus spp. [23,24]. These nutrigenomic studies showed that the mucosal responses to distinct Lactobacilli are profoundly different, illustrating the specificity of the host responses to specific bacterial strains and/or species [24] or even different preparations of the same bacterial strain [23]. Many effects elicited by probiotics are dependent on epigenetic modulation of gene expression [25]. These effects could be important during critical periods of early development, for example, in the development and programming of immune tolerance in the newborn [26].

### 4. Animal Models

Numerous animal and human studies have been performed to test the potential effects of various strains of probiotic bacteria. In this context, one of the most extensively studied probiotics worldwide is LGG. Preventive and therapeutic properties of LGG related to atopic diseases, particularly in infants with CMA, have been reported [27]. Animal models for food allergy provide an interesting tool to perform mechanistic research and to investigate the safety and efficacy of new therapeutic and preventive approaches for food allergy. Much progress has been made in recent years in developing an animal model of CMA. In particular, animal models for CMA using oral sensitization are mimicking the human situation, as children are most likely sensitized to cow’s milk via the oral route. Oral tolerance to cow’s milk proteins has been studied in these models aiming to prevent both systemic and mucosal responses. In BALB/c mice that were sensitized with cow’s milk proteins via the systemic route, oral LGG supplementation favorably modulated immune reactions by shifting Th2-dominated trends toward Th1-dominated responses [28].
5. Human Studies

5.1. Prevention of CMA

Most randomized controlled trials enrolled infants at high risk for developing allergy, which was defined as more than one family member having any allergic disease. Most of these studies looked primarily at early outcomes of allergic disease, such as eczema. Although atopic eczema is a frequent manifestation of CMA [29], it is hard to define a selective preventive effect against this type of food allergy. A large number of papers have been published on this topic with conflicting results. Differences in study design, populations, probiotic strains and dosages are responsible for these discrepancies. Prenatal and postnatal administration of high doses of selected probiotic strains seems to be the most promising approach (see Table 2).

Table 2. Main allergy prevention studies using probiotics.

| Investigators          | Population                                                                 | Probiotics and doses                                                                 | Prenatal administration | Postnatal administration | Reduction in eczema     | References |
|------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------|--------------------------|--------------------------|------------|
| Kalliomaki et al.      | Mothers with ≥1 first-degree relative (or partner) with allergic disease  | *Lactobacillus rhamnosus* GG (1 × 10^10 CFU/day) (only to mother if breast feeding post-natally) | Yes                     | 2–4 weeks before delivery | 6 months (only to baby if not breastfeeding) | at 2 and 4 years | [30–32]   |
| (2001, 2002, 2003)     |                                                                           |                                                                                      |                         |                          |                          |            |
| Rautava et al.         | Need for artificial feeding before 2 months of age                         | *Lactobacillus rhamnosus* GG (1 × 10^10 CFU/day) + *Bifidobacterium lactis* (1 × 10^10 CFU/day) added to infant formula | No                      | Yes                      | No                       | [33]       |
| (2006)                 |                                                                           |                                                                                      |                         |                          |                          |            |
| Taylor et al.          | Mother with positive SPT or documented allergic disease                    | *Lactobacillus acidophilus* (3 × 10^8 CFU/day)                                       | No                      | Yes                      | No                       | [34]       |
| (2007)                 |                                                                           |                                                                                      |                         |                          |                          |            |
| Kukkonen et al.        | One or both parents with allergic disease                                 | *Lactobacillus rhamnosus* GG and LC705 (both 5 × 10^5 CFU twice daily) + *Bifidobacterium breve* and *Propionibacterium freudenreichii* (both 2 × 10^9 CFU twice daily) | Yes                     | 2–4 weeks before delivery | 6 months direct to infant | At 2 years. | [35,36]  |
| (2007, 2009)           |                                                                           |                                                                                      |                         |                          |                          |            |
| Abrahamsson et al.     | Families with allergic disease                                            | *Lactobacillus reuteri* (1 × 10^6 CFU/day)                                           | Yes                     | 2–4 weeks before delivery | 12 months direct to infant | At 2 years | [37]     |
| (2007)                 |                                                                           |                                                                                      |                         |                          |                          |            |
| Kopp et al.            | Pregnant women from families with ≥1 first-degree relative with atopic disease | *Lactobacillus rhamnosus* GG (1 × 10^10 CFU/day) to mother if breast feeding post-natal for 3 months, then to the neonates for additional 3 months | Yes                     | 4–6 weeks before delivery | 6 months direct to infant | At 2 years | [38]     |
Table 2. Cont.

| Study            | Target Population                                                                 | Probiotic Treatment                     | Follow-up | Treatment Duration                                                                 |
|------------------|-----------------------------------------------------------------------------------|-----------------------------------------|-----------|-----------------------------------------------------------------------------------|
| Wickens et al.   | One or both parents with allergic disease                                         | *Lactobacillus rhamnosus* HN001 (1 × 10^10 CFU/day) or *Bifidobacterium lactis* HN019 (1 × 10^10 CFU/day) | Yes       | 2–5 weeks before delivery                                                        |
|                  |                                                                                   |                                         | Yes       | 2 years to infant, regardless of feeding method                                    |
|                  |                                                                                   |                                         | Yes       | at 2 years                                                                        |
| Huurre et al.    | Mother with current atopic disease                                                 | *Lactobacillus rhamnosus* GG + *Bifidobacterium lactis* (both at 1 × 10^10 CFU/day) | Yes       | from first trimester                                                            |
|                  |                                                                                   |                                         | Yes       | end of exclusive breastfeeding                                                    |
|                  |                                                                                   |                                         | No        |                                                                                   |
| Soh et al.       | Any first degree relative with SPT + allergic disease                             | *Lactobacillus rhamnosus* LPR (1 × 10^10 CFU/day) + *Bifidobacterium longum* BL999 (6 × 10^6 CFU/day) | No        | 6 months                                                                             |
|                  |                                                                                   |                                         | Yes       | at 1 year                                                                         |
|                  |                                                                                   |                                         | Yes       | in infant formula                                                                  |
| Niers et al.     | Atopic disease in either mother or father plus at least one sibling                | *Lactobacillus lactis* W58 + *Bifidobacterium lactis* W52 + *Bifidobacterium bifidum* W23 (each at: 1 × 10^9 CFU/day) | Yes       | 6 weeks before delivery                                                       |
|                  |                                                                                   |                                         | Yes       | 12 months                                                                         |
|                  |                                                                                   |                                         | Yes       | (direct to infant)                                                                 |
| West et al.      | Atopic disease in either mother or sibling                                          | *Lactobacillus paracasei* strain F19 (1 × 10^9 CFU/day in weaning cereal) | No        | 4–13 months                                                                         |
|                  |                                                                                   |                                         | Yes       | during weaning                                                                    |
| Dotterud et al.  | Unselected population                                                             | *Lactobacillus rhamnosus* GG + *Lactobacillus acidophilus* LA5 + *Bifidobacterium lactis* Bb-12 (each at 5 × 10^8 CFU/day) | Yes       | 36 weeks                                                                           |
|                  |                                                                                   |                                         | No        | Given to the breastfeeding mother for 3 months                                     |
|                  |                                                                                   |                                         | Yes       | at 1 year                                                                         |
| Kim et al.       | Pregnant women with a family history of allergic diseases                          | *Bifidobacterium bifidum* BGN4 + *Bifidobacterium lactis* AD011 and *Lactobacillus acidophilus* AD031 (each at 1.6 × 10^9 CFU/day) in 0.72 g of maltodextrin and 0.8 g of alpha-corn | Yes       | 4–8 weeks before delivery                                                      |
|                  |                                                                                   |                                         | Yes       | 6 months after delivery                                                           |
|                  |                                                                                   |                                         | Yes       | at 1 year                                                                         |
| Boyle et al.     | Pregnant women carrying infants at high risk of allergic disease                  | *Lactobacillus rhamnosus* GG (1.8 × 10^10 CFU/day) | Yes       | from 36 weeks gestation until delivery                                             |
|                  |                                                                                   |                                         | No        | No                                                                               |
|                  |                                                                                   |                                         | No        | at 1 year                                                                         |
| Rautava et al.   | Mothers with allergic disease and atopic sensitization                             | *Lactobacillus rhamnosus* LPR + *Bifidobacterium longum* BL999 or *Lactobacillus paracasei* ST11 + *Bifidobacterium longum* BL999 (each at 1 × 10^7 CFU/day) | Yes       | 2 months                                                                           |
|                  |                                                                                   |                                         | Yes       | 2 months of breast feeding                                                        |
|                  |                                                                                   |                                         | Yes       |                                                                                   |

SPT: skin prick test; CFU: colony-forming unit.

5.2. Treatment of CMA

The first objective in the treatment of CMA is the rapid resolution of symptoms. At this time, the only proven treatment consists of elimination of cow’s milk protein from the diet. For infants receiving standard formulas, a hypoallergenic formula is indicated. Administration of LGG to food-allergic
Nutrients 2013, 5 657

children (age < 2 years, challenge-proven and mild-to-moderate eczema) improved the eczema score significantly [48]. Studies in infants with eczema who received formulas supplemented with LGG showed benefits in decreasing gastrointestinal symptoms [49]. For instance, after a challenge study in infants allergic to cow’s milk proteins, fecal IgA levels were detected to be higher, and TNF-α levels were lower in the LGG applied group compared to the placebo [50]. Nermes et al. [51] investigated the interaction of LGG with skin and intestinal microflora and humoral immunity in infants with atopic dermatitis. This study showed a statistically significant decrease of IgA- and IgM-secreting cells one month after starting an intervention with extensively hydrolyzed casein formula (eHCF) supplemented with LGG. This might indirectly indicate that LGG enhances gut barrier function and accelerates immunological maturation in infants with atopic dermatitis. Especially, the finding of significant increase in memory B cells in LGG treated infants could be of particular importance [51]. Moreover, LGG is able to induce IFN-γ secretion in infants with CMA and in infants with IgE-associated dermatitis, but not in infants without CMA. This supports the view that the pattern of intestinal microflora may be aberrant in infants with an atopic predisposition, and the beneficial effects of probiotics are evident only in this group [52]. The addition of LGG to an eHCF significantly improved the recovery of the inflamed colonic mucosa if compared to that obtained with eHCF alone in infants with blood in the stool and CMA-induced colitis, as indicated indirectly by greater decreases in fecal calprotectin and in the number of infants with persistence of occult blood in stools after 1 month [53].

The second objective in the treatment of CMA is tolerance acquisition. Hol, J. et al. [54] showed that supplementation of a combination of Lactobacillus casei CRL431 and Bifidobacterium lactis Bb-12 to an extensively hydrolyzed formula failed to induce additional or accelerated cow’s milk (CM) tolerance during 12 months of treatment in infants with CMA. In contrast, we recently demonstrated that an eHCF containing LGG was able to accelerate the development of tolerance acquisition in infants affected by CMA. Infants (aged 1–12 months), consecutively referred for strongly suspected CMA, but still receiving cow’s milk proteins, were invited to participate in the study. Subjects were randomly allocated to one of the two groups of dietary interventions: group 1, received an eHCF and group 2 received an eHCF containing LGG (at least 1.4 × 10⁷ CFU/100 mL). After 12 months, the double-blind placebo-controlled food challenge (DBPCFC) was negative in 15 of 28 infants in the control group (53.6%) and in 22 of 27 infants receiving the eHCF containing LGG (81.5%, p = 0.027). These findings suggest an innovative approach for infants affected by CMA, namely an “active dietotherapy” able to reduce the time of tolerance acquisition [55].

6. Safety

The addition of probiotics in formulas used for the management of CMA requires that they be proven safe and are well tolerated. According to the European Society of Pediatric Gastroenterology and Nutrition (ESPGHAN) and the American Academy of Pediatrics, a formula must be tested in a properly designed DBPCFC and can be considered hypoallergenic when demonstrated with 95% confidence that at least 90% of infants and children with confirmed CMA would have no reaction to the formula under double-blind, placebo-controlled conditions. LGG has over 25 years of safe use, including administration to preterm infants. Recently, Muraro et al. [56] demonstrated that an eHCF
remains hypoallergenic following the addition of LGG, satisfying both the ESPGHAN and American Academy of Pediatrics guidelines.

An emerging problem is the observation that some probiotic compounds that are currently on the market may contain hidden allergens of food and may not be safe for subjects with CMA. Thus, more accurate screening tests to detect residual food proteins in end products are necessary to assess the safety of these products for food allergic patients. For allergic subjects, we would only recommend well characterized products with better information on their labels about the content of cow’s milk proteins [57].

7. Conclusions

An increasing amount of evidence suggests the role of select probiotics in prevention or treatment of CMA. These data support the importance of a “nutritional immunology approach” able not only to efficiently cure the symptoms, but also to accelerate tolerance acquisition in children with CMA. However, as a result of strain, dose and product specificities and in order to be in agreement with recommendations of official and scientific organizations, it is important that randomized, controlled trials are performed for each commercialized product.

Conflict of Interest

In the previous five years, the research group received funding from: Italian Ministry of Health, Italian Ministry of University and Scientific Research, Italian Agency of Drug (AIFA), National Foundation of Thermals, Mead Johnson Nutritionals, Humana, Campania Region. No other potential conflicts of interest were reported. The authors alone are responsible for the content and writing of the paper.

References

1. Skripak, J.M.; Matsui, E.C.; Mudd, K.; Wood, R.A. The natural history of IgE-mediated cow’s milk allergy. J. Allergy Clin. Immun. 2007, 120, 1172–1177.
2. Berni Canani, R.; Nocerino, R.; Terrin, G.; Leone, L.; Troncone, R. Hospital admissions for food-induced anaphylaxis in Italian children. Clin. Exp. Allergy 2012, 42, 1813–1814.
3. Gourbeyre, P.; Denery, S.; Bodinier, M. Probiotics, prebiotics, and synbiotics: Impact on the gut immune system and allergic reactions. J. Leukoc. Biol. 2011, 89, 685–695.
4. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of gut microbiota on human health: An integrated view. Cell 2012, 16, 1258–1270.
5. Nakayama, J.; Kobayashi, T.; Tanaka, S.; Korenori, Y.; Tateyama, A.; Sakamoto, N.; Kiyohara, C.; Shirakawa, T.; Sonomoto, K. Aberrant structures of fecal bacterial community in allergic infants profiled by 16S rRNA gene pyrosequencing. FEMS Immunol. Med. Microbiol. 2011, 63, 397–406.
6. Guidelines for the Evaluation of Probiotics in Food. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Available online: http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf (accessed on 13 March 2012).
7. Nutraceuticals: Global Markets and Processing Technologies. Available online: http://www.bccresearch.com/report/nutraceuticals-marketsprocessing-technologies-fod013d.html (accessed on 18 June 2012).

8. Mowat, A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 2003, 3, 331–341.

9. Vighi, G.; Marcucci, F.; Sensi, L.; di Cara, G.; Frati, F. Allergy and the gastrointestinal system. Clin. Exp. Immunol. 2008, 153, 3–6.

10. Romagnani, S. Regulation of the development of type 2 T-helper cells in allergy. Curr. Opin. Immunol. 1994, 6, 838–846.

11. Bjorksten, B. Environmental influences on the development of the immune system: Consequences for disease outcome. Nestlé Nutr. Workshop Ser. Pediatr. Program. 2008, 61, 243–254.

12. Berin, M.C.; Mayer, L. Can we produce true tolerance in patients with food allergy? J. Allergy Clin. Immunol. 2013, 131, 14–22.

13. Rodriguez, B.; Prioult, G.; Hacini-Rachinel, F.; Moine, D.; Bruttin, A.; Ngom-Bru, C.; Labellie, C.; Nicolis, I.; Berger, B.; Mercenier, A.; et al. Infant gut microbiota is protective against cow’s milk allergy in mice despite immature ileal T-cell response. FEMS Microbiol. Ecol. 2011, 79, 192–202.

14. Atarashi, K.; Tanoue, T.; Shima, T.; Imaoka, A.; Kuwahara, T.; Momose, Y.; Cheng, G.; Yamasaki, S.; Saito, T.; Ohba, Y.; et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331, 337–341.

15. Apostolou, E.; Pelto, L.; Kirjavainen, P.V.; Isolauri, E.; Salminen, S.J.; Gibson, G.R. Differences in the gut bacterial flora of healthy and milk-hypersensitive adults, as measured by fluorescence in situ hybridization. FEMS Immunol. Med. Microbiol. 2001, 30, 217–221.

16. Özdemir, Ö. Various effects of different probiotic strains in allergic disorders: An update from laboratory and clinical data. Clin. Exp. Immunol. 2010, 160, 295–304.

17. Fukushima, Y.; Kawata, Y.; Hara, H.; Terada, A.; Mitsuoka, T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int. J. Food Microbiol. 1998, 42, 39–44.

18. Sütas, Y.; Soppi, E.; Korhonen, H.; Syväoja, E.L.; Saxelin, M.; Rokka, T.; Isolauri, E. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes. J. Allergy Clin. Immunol. 1996, 98, 216–224.

19. Rosenfeldt, V.; Benfeldt, E.; Valerius, N.H.; Paerregaard, A.; Michaelsen, K.F. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J. Pediatr. 2004, 145, 612–616.

20. Yan, F.; Cao, H.; Cover, T.L.; Washington, M.K.; Polk, D.B. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007, 132, 562–575.

21. Rousseaux, C.; Thuru, X.; Gelot, A.; Barnich, N.; Neut, C.; Dubuquoy, L.; Dubuquoy, C.; Merour, E.; Geboes, K.; Chamaillard, M.; et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 2007, 13, 35–37.

22. Klaenhammer, T.R.; Kleerebezem, M.; Kopp, M.V.; Rescigno, M. The impact of probiotics and prebiotics on the immune system. Nat. Rev. Immunol. 2012, 12, 729–734.
23. Van Baarlen, P.; Troost, F.J.; van Hemert, S.; van der Meer, C.; de Vos, W.M.; de Groot, P.J.; Hooiveld, G.J.; Brummer, R.J.; Kleerebezem, M. Differential NF-κB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 2371–2376.

24. Van Baarlen, P.; Troost, F.; van der Meer, C.; Hooiveld, G.; Boeckxhoven, M.; Brummer, R.J.; Kleerebezem, M. Human mucosal *in vivo* transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 4562–4569.

25. Berni Canani, R.; di Costanzo, M.; Leone, L.; Bedogni, G.; Brambilla, P.K.; Cianfarani, S.; Nobili, V.M.; Pietrobelli, A.; Agostoni, C. Epigenetic mechanisms elicited by nutrition in early life. *Nutr. Res. Rev.* **2011**, *24*, 198–205.

26. Berni Canani, R.; di Costanzo, M.; Leone, L. The epigenetic effects of butyrate: Potential therapeutic implications for clinical practice. *Clin. Epigenetics* **2012**, *4*, 4.

27. Berni Canani, R.; di Costanzo, M.; Pezzella, V.; Cosenza, L.; Granata, V.; Terrin, G.; Nocerino, R. The potential therapeutic efficacy of *Lactobacillus* GG in children with food allergies. *Pharmaceuticals* **2012**, *5*, 655–664.

28. Thang, C.L.; Baurhoo, B.; Boye, J.I.; Simpson, B.K.; Zhao, X. Effects of *Lactobacillus rhamnosus* GG supplementation on cow’s milk allergy in a mouse model. *Allergy Asthma Clin. Immunol.* **2011**, *7*, 20.

29. Berni Canani, R.; Ruotolo, S.; Discepolo, V.; Troncone, R. The diagnosis of food allergy in children. *Curr. Opin. Pediatr.* **2008**, *20*, 584–589.

30. Kalliomaki, M.; Salminen, S.; Arvilommi, H.; Kero, P.; Koskinen, P.; Isolauri, E. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. *Lancet* **2001**, *357*, 1076–1079.

31. Rautava, S.; Kalliomaki, M.; Isolauri, E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. *J. Allergy Clin. Immunol.* **2002**, *109*, 119–121.

32. Kalliomaki, M.; Salminen, S.; Poussa, T.; Arvilommi, H.; Isolauri, E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet* **2003**, *361*, 1869–1871.

33. Rautava, S.; Arvilommi, H.; Isolauri, E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. *Pediatr. Res.* **2006**, *60*, 221–224.

34. Taylor, A.L.; Dunstan, J.A.; Prescott, S.L. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: A randomized controlled trial. *J. Allergy Clin. Immunol.* **2007**, *119*, 184–191.

35. Kukkonen, K.; Savilahti, E.; Haahetla, T.; Juntunen-Backman, K.; Korpela, R.; Poussa, T.; Tuure, T.; Kuitunen, M. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial. *J. Allergy Clin. Immunol.* **2007**, *119*, 192–198.

36. Kuitunen, M.; Kukkonen, K.; Juntunen-Backman, K.; Korpela, R.; Poussa, T.; Tuure, T.; Haahetla, T.; Savilahti, E. Probiotics prevent IgE-associated allergy until age 5 years in cesarean delivered children but not in the total cohort. *J. Allergy Clin. Immunol.* **2009**, *123*, 335–341.
37. Abrahamsson, T.R.; Jakobsson, T.; Bottcher, M.F.; Fredrikson, M.; Jenmalm, M.C.; Björkstén, B.; Oldaeus, G. Probiotics in prevention of IgE-associated eczema: A double-blind, randomized, placebo-controlled trial. *J. Allergy Clin. Immunol.* **2007**, *119*, 1174–1180.

38. Kopp, M.V.; Hennemuth, I.; Heinzmann, A.; Urbanek, R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: No clinical effects of *Lactobacillus* GG supplementation. *Pediatrics* **2008**, *121*, e850–e856.

39. Wickens, K.; Black, P.N.; Stanley, T.V.; Mitchell, E.; Fitzharris, P.; Tannock, G.W.; Purdie, G.; Crane, J.; Probiotic Study Group. A differential effect of 2 probiotics in the prevention of eczema and atopy: A doubleblind, randomized, placebo-controlled trial. *J. Allergy Clin. Immunol.* **2008**, *122*, 788–794.

40. Huurre, A.; Laitinen, K.; Rautava, S.; Korkeamaki, M.; Isolauri, E. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: A double-blind placebo-controlled study. *Clin. Exp. Allergy* **2008**, *38*, 1342–1348.

41. Soh, S.E.; Aw, M.; Gerez, I.; Rauff, M.; Ng, Y.P.; Wong, H.B.; Pai, N.; Lee, B.W.; Shek, L.P. Probiotic supplementation in the first 6 months of life in at risk Asian infants—Effects on eczema and atopic sensitization at the age of 1 year. *Clin. Exp. Allergy* **2009**, *39*, 571–578.

42. West, C.E.; Hammarstrom, M.L.; Hernell, O. Probiotics during weaning reduce the incidence of eczema. *Pediatr. Allergy Immunol.* **2009**, *20*, 430–437.

43. Dotterud, C.; Oien, T.; Storro, O.; Johnsen, R. Probiotic supplementation given to mothers in primary prevention of allergic diseases in early childhood—A randomised controlled trial in an unselected population. *Allergy* **2009**, *64*, 64.

44. Kim, J.Y.; Kwon, J.H.; Ahn, S.H.; Lee, S.I.; Han, Y.S.; Choi, Y.O.; Lee, S.Y.; Ahn, K.M.; Ji, G.E. Effect of probiotic mix (*Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus*) in the primary prevention of eczema: A double-blind, randomized, placebo-controlled trial. *Pediatr. Allergy Immunol.* **2010**, *21*, e386–e393.

45. Boyle, R.J.; Ismail, I.H.; Kivivuori, S.; Licciardi, P.V.; Robins-Browne, R.M.; Mah, L.J.; Axelrad, C.; Moore, S.; Donath, S.; Carlin, J.B.; *et al.* *Lactobacillus* GG treatment during pregnancy for the prevention of eczema: A randomized controlled trial. *Allergy* **2011**, *66*, 509–516.

46. Niers, L.; Martín, R.; Rijkers, G.; Sengers, F.; Timmerman, H.; van Uden, N.; Smidt, H.; Kimpen, J.; Hoekstra, M. The effects of selected probiotic strains on the development of eczema (The PandA study). *Allergy* **2009**, *64*, 1349–1358.

47. West, C.E.; Hammarstrom, M.L.; Hernell, O. Probiotics during weaning reduce the incidence of eczema. *Pediatr. Allergy Immunol.* **2009**, *20*, 430–437.

48. Dotterud, C.; Oien, T.; Storro, O.; Johnsen, R. Probiotic supplementation given to mothers in primary prevention of allergic diseases in early childhood—A randomised controlled trial in an unselected population. *Allergy* **2009**, *64*, 64.

49. Kim, J.Y.; Kwon, J.H.; Ahn, S.H.; Lee, S.I.; Han, Y.S.; Choi, Y.O.; Lee, S.Y.; Ahn, K.M.; Ji, G.E. Effect of probiotic mix (*Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus*) in the primary prevention of eczema: A double-blind, randomized, placebo-controlled trial. *Pediatr. Allergy Immunol.* **2010**, *21*, e386–e393.

50. Boyle, R.J.; Ismail, I.H.; Kivivuori, S.; Licciardi, P.V.; Robins-Browne, R.M.; Mah, L.J.; Axelrad, C.; Moore, S.; Donath, S.; Carlin, J.B.; *et al.* *Lactobacillus* GG treatment during pregnancy for the prevention of eczema: A randomized controlled trial. *Allergy* **2011**, *66*, 509–516.

51. Rautava, S.; Kainonen, E.; Salminen, S.; Isolauri, E. Maternal probiotic supplementation during pregnancy and breast feeding reduces the risk of eczema in infant. *J. Allergy Clin. Immunol.* **2012**, *130*, 1355–1360.

52. Majamaa, H.; Isolauri, E. Probiotics: A novel approach in the management of food allergy. *J. Allergy Clin. Immun.***1997**, *99*, 179–185.

53. Isolauri, E.; Arvola, T.; Sutas, Y.; Moilanen, E.; Salminen, S. Probiotics in the management of atopic eczema. *Clin. Exp. Allergy* **2000**, *30*, 1604–1610.

54. Isolauri, E. Studies on *Lactobacillus* GG in food hypersensitivity disorders. *Nutr. Today Suppl.* **1996**, *31*, 285–315.
51. Nermes, M.; Kantele, J.M.; Atosuo, T.J.; Salminen, S.; Isolauri, E. Interaction of orally administered *Lactobacillus rhamnosus* GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. *Clin. Exp. Allergy* 2010, 41, 370–377.

52. Pohjavuori, E.; Viljanen, M.; Korpela, R.; Kuitunen, M.; Tiittanen, M.; Vaarala, O.; Savilahti, E. *Lactobacillus* GG effect in increasing IFN-γ production in infants with cow’s milk allergy. *J. Allergy Clin. Immun.* 2004, 114, 131–136.

53. Baldassarre, M.E.; Laforgia, N.; Fanelli, M.; Laneve, A.; Grosso, R.; Lifschitz, C. *Lactobacillus* GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. *J. Pediatr.* 2010, 156, 397–401.

54. Hol, J.; van Leer, E.H.; Elink Schuurman, B.E.; de Ruiter, L.F.; Samsom, J.N.; Hop, W.; Neijens, H.J.; de Jongste, J.C.; Nieuwenhuis, E.E.; Cow’s Milk Allergy Modified by Elimination and *Lactobacilli* study group. The acquisition of tolerance toward cow’s milk through probiotic supplementation: A randomized, controlled trial. *J. Allergy Clin. Immunol.* 2008, 121, 1448–1454.

55. Berni Canani, R.; Nocerino, R.; Terrin, G.; Coruzzo, A.; Cosenza, L.; Leone, L.; Troncone, R. Effect of extensively hydrolyzed casein formula supplemented with *Lactobacillus* GG on tolerance acquisition in infants with cow’s milk allergy: A randomized trial. *J. Allergy Clin. Immun.* 2012, 129, 580–582.

56. Muraro, A.; Hoekstra, M.O.; Meijer, Y.; Lifschitz, C.; Wampler, J.L.; Harris, C.; Scalabrin, D.M. Extensively hydrolysed casein formula supplemented with *Lactobacillus rhamnosus* GG maintains hypoallergenic status: Randomized double-blind, placebo-controlled crossover trial. *BMJ Open* 2012, 5, 2.

57. Martín-Muñoz, M.F.; Fortuni, M.; Caminoa, M.; Belver, T.; Quirce, S.; Caballero, T. Anaphylactic reaction to probiotics. Cow’s milk and hen’s egg allergens in probiotic compounds. *Pediatr. Allergy Immunol.* 2012, 23, 778–784.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).